plerixafor

First-line R-DA-EPOCH enables effective stem cell mobilization in most high-risk DLBCL and HGBCL patients, although a substantial proportion require PLX support. These findings suggest that R-DA-EPOCH is a feasible platform for early mobilization and ASCT in selected patients.

P2/3, N=20, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Phase classification: P3 --> P2/3

PXF + G-CSF is a more effective and less toxic mobilizing agent than the chemotherapy-based regimen (EC + G-CSF), and is associated with faster hematopoietic reconstruction without increasing the risk of tumor progression. This regimen may be considered a valuable option for stem cell mobilization.

We established and validated a CSC-related prognostic model that was closely associated with macrophage polarization and clinical outcomes in STAD. CXCR4 was identified as the key gene in this model, which unregulated lactate secretion to drive M2 macrophage polarization and maintain CSC properties in STAD, and may serve as a putative regulatory factor in STAD progression. The CXCR4 inhibitor AMD3100 exerted significant anti-tumor effects in vitro, suggesting that CXCR4 may serve as a promising prognostic biomarker and a candidate target for STAD.

Collectively, these findings identify IL-1β and CXCL12 as potential critical mediators of the inflammatory crosstalk between adipocytes and PanNET cells. Targeting this signalling axis may therefore represent a promising therapeutic strategy for PanNETs.

Plerixafor on day 4 appears to enhance PBSC collection efficiency and reduce the need for multiple apheresis sessions compared with conventional day-5 administration. These findings support consideration of earlier plerixafor use in mobilization protocols, though larger studies are warranted to confirm clinical and cost-effectiveness.

Agonists induced transient heteromerization coupled to receptor internalization, while antagonists, especially plerixafor together with maraviroc, stabilized persistent surface-associated complexes. Molecular dynamics simulations in asymmetric bilayers resembling MDA-MB-231 and MCF-10A membranes identified cholesterol-enriched receptor interfaces that prolong CXCR4-CCR5 dimer lifetimes in MDA-like membranes. These results show that GPCR heteromerization is not an intrinsic fixed property of receptor pairs, but an emergent behavior shaped by cell state, lipid environment, and ligand input.

Mobilizing peripheral blood stem cells in lymphoma patients with a single high-dose of etoposide combined with mecapegfilgrastim is effective, safe and cost-effective.

P2, N=74, Not yet recruiting, National Cancer Institute (NCI)

P1, N=12, Not yet recruiting, St. Jude Children's Research Hospital

P1, N=66, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | Trial completion date: Nov 2027 --> May 2028 | Trial primary completion date: Nov 2027 --> May 2028

In our cohort, the incorporation of ASCT into multimodality therapy was feasible with resource-adapted strategies; however, this did not translate into a meaningful improvement in survival outcomes when compared with our historical non-transplant cohort.